Company Insights

TGTX customer relationships

Explore interactive graphBrowse insights index
TGTX customer relationship map

TG Therapeutics (TGTX) — Customer Map and Commercial Signals

TG Therapeutics is a commercial-stage biopharma that monetizes primarily through sales of its flagship monoclonal antibody BRIUMVI in the U.S. and via ex‑U.S. licensing/commercialization partnerships. The company recognizes product revenue from direct U.S. sales and records license and milestone receipts plus shipments to partners who commercialize BRIUMVI outside North America, creating a hybrid revenue mix of direct sales, license income, and partner-supplied product shipments. Explore Null Exposure for structured relationship intelligence: https://nullexposure.com/

The investment thesis in one line

TG Therapeutics delivers visible, recurring product cash flow from BRIUMVI while leveraging selective licensing to scale ex‑U.S. distribution; the investor case centers on sustaining U.S. sales while monetizing international rights through partners that accelerate market access without commensurate SG&A expansion.

How the customer relationships fit the commercial strategy

TG’s customer engagements are twofold: (1) end‑market selling in North America, where TG acts as the seller and recognizes highest-margin product revenue; and (2) exclusive ex‑U.S. commercialization licenses, where TG grants partners rights and records product shipments, license revenue, milestones, and deferred revenue tied to fulfillment obligations. This structure supports a capital-efficient geographic expansion while preserving control of U.S. commercialization economics.

If you’re mapping partner revenue exposure and contractual obligations for diligence, start with the company’s public filings and partner press releases available via https://nullexposure.com/.

Customer relationships on the record

Neuraxpharm / Neuraxpharm Pharmaceuticals

TG Therapeutics granted Neuraxpharm exclusive commercialization rights for BRIUMVI in territories outside the U.S., Canada and Mexico, and began shipments to Neuraxpharm in November 2023; Neuraxpharm purchases contributed to ex‑U.S. product revenue recognized by TG. According to TG’s FY2024 Form 10‑K, the company began shipping BRIUMVI to its ex‑U.S. licensing partner Neuraxpharm in November 2023, and the commercialization agreement was signed on July 28, 2023. (Source: TG Therapeutics 2024 Form 10‑K.)

TG continues to record partner‑related product revenue and commercial milestones: TG reported $3.7 million of sales to Neuraxpharm in 2024 and $12.8 million in 2025, with quarterly disclosures indicating partner shipments accounted for $6.4 million of product revenue in a Q4 2025 quarter. (Sources: Globenewswire press release, Feb 26, 2026; Q4 2025 earnings call transcript reported by InsiderMonkey.)

Biogen

Biogen is a strategic commercialization collaborator linked to the U.S. rollout of ublituximab (BRIUMVI); Biogen collaborated on bringing BRIUMVI to market and TG cited the Biogen partnership as part of its first commercial milestone in December 2022. MarketBeat and analyst commentary reference Biogen’s role in the initial U.S. commercialization milestone achieved in December 2022. (Source: MarketBeat report referencing TG disclosures, FY2026 context.)

What the contractual signals say about risk and upside

TG’s reported constraints and contract excerpts illuminate operating dynamics that are material to valuation and partnership diligence:

  • Contracting posture — licensing is a deliberate part of the model. Company disclosures identify a licensing revenue stream, including a $140 million non‑refundable upfront license recognized in 2023, which demonstrates TG’s willingness to monetize IP upfront and treat large license payments as distinct performance obligations. This is a company‑level signal of strategic reliance on licensing income to de‑risk geographic scale.

  • Geography split — U.S. is the cash engine; EMEA is partner‑led. TG commercially launched BRIUMVI in the U.S. (January 26, 2023) and reports robust U.S. sales; ex‑U.S. commercialization is handled through partners, notably Neuraxpharm in EMEA, where TG recorded an EU launch milestone payment and partner sales. (Evidence from company filings and regulatory approval disclosures.)

  • Seller role and revenue concentration. TG reports material product revenue (e.g., $313.7 million in BRIUMVI product revenue for 2024) as the seller in the U.S., indicating a core reliance on direct sales for margin capture, with partner shipments contributing a smaller—but strategically important—slice of product revenue. (Company 10‑K figures and revenue reporting.)

  • Active, contractually binding partner obligations. The company disclosed an unconditional receivable of $1.5 million from Neuraxpharm, $23.5 million recorded as deferred revenue, and $3.7 million of partner‑related product sales recognized in 2024, demonstrating that partner agreements carry both current receivables and unsatisfied performance obligations. Because the 10‑K explicitly names Neuraxpharm in these excerpts, these figures are attributable to that relationship. (Source: TG Therapeutics 2024 Form 10‑K.)

  • Product focus and maturity. Management signals that BRIUMVI is the core commercial product underpinning current revenue while pipeline assets (e.g., azer‑cel) are being developed; this concentration creates clear near‑term revenue visibility but elevates single‑product risk until additional approvals or indications diversify revenue.

Explore a deeper partner map and commercial exposure analysis at https://nullexposure.com/ to support underwriting or operational planning.

Investor implications: what to watch next

  • Revenue cadence vs. fulfillment obligations. Monitor deferred revenue roll‑off and partner receivable collections from Neuraxpharm to ensure license milestones and shipments translate into cash rather than accrual volatility.
  • Ex‑U.S. scale via partners. Neuraxpharm’s performance and regional launch execution will determine how much incremental ex‑U.S. revenue TG can capture without building direct commercial infrastructure.
  • U.S. sales retention and reimbursement environment. U.S. net product sales remain the primary margin driver; payor acceptance and competitive dynamics will determine the sustainability of those cashflows.

Bottom line and next steps

  • BRIUMVI is the commercial backbone; partners like Neuraxpharm extend reach while limiting TG’s direct SG&A exposure. The company’s mix of upfront licenses, milestones, and product shipments produces both one‑time and recurring revenue streams that influence near‑term cash flow stability.
  • Contracts are active and financially consequential. The explicit receivables, deferred revenue and reported partner sales confirm ongoing commercial execution in ex‑U.S. territories.
  • Key diligence priorities: verify milestone payment schedules, fulfillment windows tied to deferred revenue, and partner launch performance metrics in EMEA.

For analysts and operators building counterparty exposure models, the detailed relationship intelligence on TG Therapeutics is available for deeper review at https://nullexposure.com/. For a tailored commercial exposure briefing or competitor map, contact our team through the site: https://nullexposure.com/ — we provide structured partner insights to support underwriting and strategic decisions.